For Biden, a New Virus Dilemma: How to Handle a Looming Glut of Vaccine – The New York Times

But while Johnson & Johnson has lagged behind the other manufacturers, its technology carries enormous promise for mass production because it can deliver many more doses per lot.

Later this year, when Merck & Company is expected to begin producing Johnson & Johnson’s vaccine, it could churn out 100 million doses a month — or as much as Pfizer and Moderna together deliver monthly. The White House hailed the deal between Johnson & Johnson and Merck, but by the time production gets up to speed, those doses may be bound for a growing surplus or for export.

One option is to ship the frozen vaccine that will be manufactured in Merck’s plant overseas, where it can be bottled much more cheaply. Of the $10 that the federal government has agreed to pay for a dose of Johnson & Johnson’s vaccine, the drug substance itself accounts for only about 30 cents, federal officials said. The rest is the so-called fill-and-finish cost.

If AstraZeneca wins emergency use authorization from U.S. regulators, that will throw still more shots into the mix. Officials expect about 50 million doses to be ready for delivery in May.

But Biden administration officials are skittish about AstraZeneca’s vaccine. It appears to be roughly as effective as Johnson & Johnson’s but requires an additional shot, meaning a more complicated rollout. Some health officials worry that if there are already enough doses in the pipeline to cover every adult who wants a shot, introducing a fourth vaccine will just confuse people.

On the other hand, if the administration decides to donate the AstraZeneca doses without offering any to its own citizens, other countries might conclude that the United States lacks confidence in the vaccine’s safety or effectiveness.

“As we gain more confidence in the doses that we have and the ability or the need or not to be boosting, then we can make a more definitive statement about what the role of the AZ product is going to be in the United States” should it gain clearance, Dr. Fauci said in an interview this week, “but right now I think it’s too premature to say anything.”

Sheryl Gay Stolberg, Benjamin Mueller and Matina Stevis-Gridneff contributed reporting. Kitty Bennett contributed research.

Sorgente articolo:
For Biden, a New Virus Dilemma: How to Handle a Looming Glut of Vaccine – The New York Times

User ID Campaign ID Link
d9a95efa0a2845057476957a427b0499 l-99999994 Email Advertising Free Trial
d9a95efa0a2845057476957a427b0499 l-99999996 Free Trial Webinar
d9a95efa0a2845057476957a427b0499 l-99999984 Free Web Hosting
d9a95efa0a2845057476957a427b0499 l-99999993 B2B Keyword tool